去年，Edwards Lifesciences Corp表现最佳的业务板块Transcatheter Aortic Valve Replacement实现营收4.49B美元。United States的营收贡献最高，去年达到3.54B美元。最近一个季度，截至2026-06-30，Edwards Lifesciences Corp表现最佳的业务板块Transcatheter Aortic Valve Replacement实现营收1.26B美元。United States的营收贡献最高，达到1.00B美元。

业务

营业收入

占比

年报

年报

单季报

Transcatheter Aortic Valve Replacement

Surgical Heart Valve Therapy

Transcatheter Mitral and Tricuspid Therapies

Critical Care

Transcatheter Heart Valve Therapy

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Transcatheter Aortic Valve Replacement

4.49B(73.96%)

4.11B(75.49%)

3.88B(65.34%)

3.52B(66.14%)

3.42B(65.41%)

2.86B(65.14%)

2.74B(62.97%)

--(--)

Surgical Heart Valve Therapy

1.03B(16.96%)

981.30M(18.04%)

932.60M(15.71%)

829.70M(15.60%)

889.10M(16.99%)

761.80M(17.37%)

841.70M(19.36%)

761.60M(20.46%)

807.10M(23.49%)

774.90M(26.15%)

785.00M(31.48%)

Transcatheter Mitral and Tricuspid Therapies

550.60M(9.07%)

352.10M(6.47%)

197.60M(3.33%)

116.10M(2.18%)

86.00M(1.64%)

41.80M(0.95%)

28.20M(0.65%)

--(--)

Critical Care

--(--)

928.10M(15.63%)

855.00M(16.07%)

834.90M(15.96%)

725.40M(16.54%)

740.20M(17.02%)

674.50M(18.12%)

601.00M(17.49%)

560.30M(18.91%)

528.40M(21.19%)

Transcatheter Heart Valve Therapy

--(--)

2.29B(61.42%)

2.03B(59.01%)

1.63B(54.95%)

1.18B(47.33%)

地区

营业收入

占比

年报

年报

单季报

United States

Europe

Rest of the world

Japan

Unallocated

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

3.54B(58.39%)

3.21B(58.94%)

2.95B(58.84%)

2.63B(58.88%)

2.96B(56.63%)

2.52B(57.38%)

2.53B(58.25%)

Europe

1.52B(25.01%)

1.32B(24.30%)

1.18B(23.56%)

1.04B(23.30%)

1.19B(22.75%)

945.20M(21.55%)

926.10M(21.30%)

Rest of the world

652.30M(10.75%)

572.00M(10.52%)

531.10M(10.60%)

436.00M(9.77%)

550.20M(10.52%)

451.50M(10.29%)

433.30M(9.97%)

Japan

354.70M(5.85%)

339.80M(6.25%)

350.80M(7.00%)

359.50M(8.05%)

528.90M(10.11%)

448.60M(10.23%)

441.40M(10.15%)

Unallocated

--(--)

24.20M(0.55%)

14.50M(0.33%)